Cargando…

Endocrine Therapy-Based Strategies for Metastatic Breast Cancer with Different Endocrine Sensitivity Statuses: A Systematic Review and Network Meta-Analysis

SIMPLE SUMMARY: Over the past few years, a great deal of considerable research has been conducted to develop more effective targeted agents for metastatic breast cancer (mBC) patients. This systematic review and meta-analysis of 47 randomized clinical trials identified CDK4/6i + Fulvestrant 500 as t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Jiani, Han, Yiqun, Wang, Jiayu, Li, Qing, Xu, Binghe
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Systematic Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9776369/ https://www.ncbi.nlm.nih.gov/pubmed/36551586 http://dx.doi.org/10.3390/cancers14246100

Ejemplares similares

Optimal Choice as First-Line Therapy for Patients with Triple-Negative Breast Cancer: A Bayesian Network Meta-Analysis
por: Han, Yiqun, et al.
Publicado: (2022)

Comparative Efficacy of Tyrosine Kinase Inhibitors and Antibody–Drug Conjugates in HER2-Positive Metastatic Breast Cancer Patients with Brain Metastases: A Systematic Review and Network Meta-Analysis
por: Wang, Yan, et al.
Publicado: (2022)

Endocrine-Based Treatments in Clinically-Relevant Subgroups of Hormone Receptor-Positive/HER2-Negative Metastatic Breast Cancer: Systematic Review and Meta-Analysis
por: Schettini, Francesco, et al.
Publicado: (2021)

Efficacy and Safety of Bevacizumab in Pretreated Metastatic Breast Cancer: A Systematic Review and Meta-Analysis
por: Li, Zhijun, et al.
Publicado: (2022)

Updates in endocrine therapy for metastatic breast cancer
por: Manohar, Poorni M., et al.
Publicado: (2022)

Longitudinal Effects of Adjuvant Endocrine Therapy on the Quality of Life of Post-menopausal Women with Non-metastatic ER+ Breast Cancer: A Systematic Review
por: Xiao, Hong, et al.
Publicado: (2018)

Endocrine therapy for the treatment of leptomeningeal carcinomatosis in luminal breast cancer: a comprehensive review
por: Fernandes, Leonor, et al.
Publicado: (2020)

Metabolic and Endocrine Toxicities of Mitotane: A Systematic Review
por: Bianchini, Marta, et al.
Publicado: (2021)

Markers of endocrine sensitivity
por: Hayes, Daniel F
Publicado: (2008)

Metastatic breast cancer: Endocrine therapy landscape reshaped
por: Salkeni, Mohamad Adham, et al.
Publicado: (2017)

Status of adjuvant endocrine therapy for breast cancer
por: Schiavon, Gaia, et al.
Publicado: (2014)

The Uncharted Landscape of Rare Endocrine Immune-Related Adverse Events
por: Mytareli, Chrysoula, et al.
Publicado: (2023)

CDK4/6 inhibitors versus PI3K/AKT/mTOR inhibitors in women with hormone receptor-positive, HER2-negative metastatic breast cancer: An updated systematic review and network meta-analysis of 28 randomized controlled trials
por: Xu, Hangcheng, et al.
Publicado: (2022)

How I treat endocrine-dependent metastatic breast cancer
por: Gombos, A., et al.
Publicado: (2023)

Treatment of Advanced Gastro-Entero-Pancreatic Neuro-Endocrine Tumors: A Systematic Review and Network Meta-Analysis of Phase III Randomized Controlled Trials
por: Ricci, Claudio, et al.
Publicado: (2021)

Novel Strategies to Improve the Endocrine Therapy of Breast Cancer
por: Castrellon, Aurelio Bartolome
Publicado: (2017)

Effect of first-line endocrine therapy in patients with hormone-sensitive advanced breast cancer: a network meta-analysis
por: Zhang, Tingting, et al.
Publicado: (2018)

Sex differences in cognition following variations in endocrine status
por: Bowman, Rachel, et al.
Publicado: (2022)

Potentially Modifiable Factors Associated with Adherence to Adjuvant Endocrine Therapy among Breast Cancer Survivors: A Systematic Review
por: Toivonen, Kirsti I., et al.
Publicado: (2020)

National strategy on endocrine disruptors.
Publicado: (1996)

Efficacy and safety of endocrine monotherapy as first-line treatment for hormone-sensitive advanced breast cancer: A network meta-analysis
por: Zhang, Jingwen, et al.
Publicado: (2017)

Chemotherapy Modulates Endocrine Therapy-Related Resistance Mutations in Metastatic Breast Cancer
por: Zhou, Dabo, et al.
Publicado: (2019)

Network Meta-Analysis of the Effectiveness of Neoadjuvant Endocrine Therapy for Postmenopausal, HR–Positive Breast Cancer
por: Wang, Wei, et al.
Publicado: (2016)

Overcoming endocrine resistance in metastatic hormone receptor-positive breast cancer
por: D’Souza, Anishka, et al.
Publicado: (2018)

Rewiring of the Endocrine Network in Triple-Negative Breast Cancer
por: Li, Kaixuan, et al.
Publicado: (2022)

Endocrine Therapy for Hormone Receptor-Positive Advanced Breast Cancer: A Nation-Wide Multicenter Epidemiological Study in China
por: Wu, Yun, et al.
Publicado: (2021)

Tumor Microenvironment Subtypes and Immune-Related Signatures for the Prognosis of Breast Cancer
por: Han, Yiqun, et al.
Publicado: (2021)

Cytotoxic Lymphocyte-Related Gene Signature in Triple-Negative Breast Cancer
por: Han, Yiqun, et al.
Publicado: (2023)

Polycystic Ovary Syndrome and Endocrine Disruptors (Bisphenols, Parabens, and Triclosan)—A Systematic Review
por: Srnovršnik, Tinkara, et al.
Publicado: (2023)

Health-related quality of life and estimation of the minimally important difference in the Functional Assessment of Cancer Therapy-Endocrine Symptom score in postmenopausal ER+/HER2- metastatic breast cancer with low sensitivity to endocrine therapy
por: Kikawa, Yuichiro, et al.
Publicado: (2022)

Real-world effectiveness and sensitivity of palbociclib plus endocrine therapy in HR+/HER2– patients with metastatic breast cancer
por: Li, Jingping, et al.
Publicado: (2021)

Current Strategies of Endocrine Therapy in Elderly Patients with Breast Cancer
por: Lee, Suk-young, et al.
Publicado: (2018)

The endocrine prevention of breast cancer.
por: Fentiman, I. S.
Publicado: (1989)

ENDOCRINE ASPECTS OF BREAST CANCER
Publicado: (1958)

Endocrine Relationships in Breast Cancer
por: Barnes, D. M.
Publicado: (1982)

SET(ER/PR): a robust 18-gene predictor for sensitivity to endocrine therapy for metastatic breast cancer
por: Sinn, Bruno V., et al.
Publicado: (2019)

The Impact of Endocrine Disruptors on Endocrine Targets
por: Gregoraszczuk, Ewa L., et al.
Publicado: (2013)

Combination cyclin-dependent kinase 4/6 inhibitors and endocrine therapy versus endocrine monotherapy for hormonal receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: A systematic review and meta-analysis
por: Zheng, Jiani, et al.
Publicado: (2020)

Novel biomarkers and prediction model for the pathological complete response to neoadjuvant treatment of triple-negative breast cancer
por: Han, Yiqun, et al.
Publicado: (2021)

Combined chemo-endocrine therapy as a potential new option for HR+/HER2− advanced breast cancer: a prospective study of fulvestrant plus oral vinorelbine
por: Wang, Xue, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_8sdgcpm674rlvvj2t8017etks0